Krystal Biotech Shares Outstanding History (KRYS)
Krystal Biotech reported 29.2M shares outstanding at the end of fiscal 2025.
View full Krystal Biotech company overviewKrystal Biotech annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 29.2M | 398,000 | +1.38% |
| 2024 | 2024-12-31 | 28.8M | 557,000 | +1.97% |
| 2023 | 2023-12-31 | 28.2M | 2.5M | +9.60% |
| 2022 | 2022-12-31 | 25.8M | 555,758 | +2.20% |
| 2021 | 2021-12-31 | 25.2M | 5.5M | +27.87% |
| 2020 | 2020-12-31 | 19.7M | 2.4M | +13.60% |
| 2019 | 2019-12-31 | 17.4M | 7.0M | +68.37% |
| 2017 | 2017-12-31 | 10.3M | 10.3M | — |
| 2016 | 2016-12-31 | 0 | — | — |
Krystal Biotech quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 29.6M | 669,000 | +2.31% |
| Q1 2026 | 2026-03-31 | 29.4M | 538,000 | +1.86% |
| Q4 2025 | 2025-12-31 | 29.2M | 398,000 | +1.38% |
| Q3 2025 | 2025-09-30 | 29.0M | 227,000 | +0.79% |
| Q2 2025 | 2025-06-30 | 28.9M | 218,000 | +0.76% |
| Q1 2025 | 2025-03-31 | 28.9M | 371,000 | +1.30% |
| Q4 2024 | 2024-12-31 | 28.8M | 557,000 | +1.97% |
| Q3 2024 | 2024-09-30 | 28.8M | 562,345 | +1.99% |
| Q2 2024 | 2024-06-30 | 28.7M | 734,084 | +2.62% |
| Q1 2024 | 2024-03-31 | 28.5M | 2.7M | +10.59% |
| Q4 2023 | 2023-12-31 | 28.2M | 2.5M | +9.60% |
| Q3 2023 | 2023-09-30 | 28.2M | 2.5M | +9.67% |
| Q2 2023 | 2023-06-30 | 28.0M | 2.3M | +9.00% |
| Q1 2023 | 2023-03-31 | 25.8M | 588,228 | +2.33% |
| Q4 2022 | 2022-12-31 | 25.8M | 3.5M | +15.85% |
| Q3 2022 | 2022-09-30 | 25.7M | 3.5M | +15.78% |
| Q2 2022 | 2022-06-30 | 25.7M | 3.5M | +15.58% |
| Q4 2021 | 2021-12-31 | 25.2M | 5.5M | +27.87% |
| Q3 2021 | 2021-09-30 | 22.2M | 2.5M | +12.84% |
| Q2 2021 | 2021-06-30 | 22.2M | 2.5M | +12.92% |
| Q1 2021 | 2021-03-31 | 22.2M | 4.8M | +27.83% |
| Q4 2020 | 2020-12-31 | 19.7M | 2.4M | +13.60% |
| Q3 2020 | 2020-09-30 | 19.7M | 2.4M | +13.86% |
| Q2 2020 | 2020-06-30 | 19.7M | 2.7M | +16.05% |
| Q1 2020 | 2020-03-31 | 17.4M | 2.9M | +20.27% |
| Q4 2019 | 2019-12-31 | 17.4M | 2.9M | +20.27% |
| Q3 2019 | 2019-09-30 | 17.3M | 6.3M | +57.64% |
| Q2 2019 | 2019-06-30 | 16.9M | 6.6M | +63.66% |
| Q1 2019 | 2019-03-31 | 14.4M | 4.1M | +40.10% |
| As of Dec 31, 2018 | 2018-12-31 | 14.4M | 4.1M | +39.99% |
| Q3 2018 | 2018-09-30 | 11.0M | 741,669 | +7.24% |
| Q2 2018 | 2018-06-30 | 10.4M | 10.4M | — |
| Q1 2018 | 2018-03-31 | 10.3M | — | — |
| Q4 2017 | 2017-12-31 | 10.3M | — | — |
| Q3 2017 | 2017-09-30 | 10.2M | — | — |
| Q4 2016 | 2016-12-31 | 0 | — | — |
Krystal Biotech shares outstanding trends
Over the last five reported fiscal years, Krystal Biotech's shares outstanding moved from 19.7M to 29.2M, a change of 9.5M. The latest reported quarter, Q2 2026, shows 29.6M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Krystal Biotech filings at SEC.gov ↗